Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 15/20 | 0.71 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.71 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.71 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.71 |
| ▸ | NQO2 | P16083 | 1/20 | 0.71 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.71 |
| ▸ | ACTR2 | P61160 | 1/20 | 0.71 |
| ▸ | CCR1 | P32246 | 5/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14270501 | 1.00 | MAPK14 (0.71) | MAPK14MAPK11MAPK13MAPK12NQO2 | |
| SCHEMBL22764065 | 0.91 | MAPK14 (0.57) | MAPK14MAPK11MAPK13MAPK12NQO2 | |
| SCHEMBL4510181 | 0.90 | MAPK14 (0.57) | MAPK14MAPK11MAPK13MAPK12NQO2 | |
| SCHEMBL14185139 | 0.89 | MAPK14 (0.65) | MAPK14MAPK11MAPK13MAPK12NQO2 | |
| SCHEMBL13936081 | 0.89 | MAPK14 (0.65) | MAPK14MAPK11MAPK13MAPK12NQO2 | |
| SCHEMBL4504045 | 0.88 | MAPK14 (0.55) | MAPK14MAPK11MAPK13MAPK12NQO2 | |
| SCHEMBL4488907 | 0.88 | MAPK14 (0.55) | MAPK14MAPK11MAPK13MAPK12NQO2 | |
| SCHEMBL4513814 | 0.87 | MAPK14 (0.54) | MAPK14MAPK11MAPK13MAPK12NQO2 | |
| SCHEMBL4505811 | 0.87 | MAPK14 (0.54) | MAPK14MAPK11MAPK13MAPK12NQO2 | |
| SCHEMBL13954893 | 0.87 | MAPK14 (0.54) | MAPK14MAPK11MAPK13MAPK12NQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3081568-B1 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | EIP PHARMA LLC (US) | 2019-11-13 | — | — | EP | disclosed |
| EP-3081568-A1 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | Eip Pharma, LLC (US) | 2016-10-19 | — | — | EP | disclosed |
| US-9427438-B2 | Compositions and methods for treating Alzheimer's disease | EIP PHARMA, LLC (US) | 2016-08-30 | — | — | US | disclosed |
| EP-2707369-B1 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | EIP PHARMA LLC (US) | 2016-07-27 | — | — | EP | disclosed |
| US-20160030431-A1 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | EIP PHARMA, LLC | 2016-02-04 | — | — | US | disclosed |
| US-20140357638-A1 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | EIP PHARMA, LLC (US) | 2014-12-04 | — | — | US | disclosed |
| WO-2012154814-A1 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | EIP PHARMA, LLC (US) | 2012-11-15 | — | — | WO | disclosed |
| US-20120289511-A1 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | EIP PHARMA, LLC (US) | 2012-11-15 | — | — | US | disclosed |
| US-7488744-B2 | Indole-type derivatives as inhibitors of p38 kinase | SCIOS, INC. (US) | 2009-02-10 | — | — | US | disclosed |
| US-7488744-B2 | Indole-type derivatives as inhibitors of p38 kinase | SCIOS, INC. (US) | 2009-02-10 | — | — | US | disclosed |
| US-7268139-B2 | Methods of promoting osteogenesis | SCIOS, INC. (US) | 2007-09-11 | — | — | US | disclosed |
| US-7244441-B2 | Stents and intra-luminal prostheses containing map kinase inhibitors | SCIOS, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| US-7244441-B2 | Stents and intra-luminal prostheses containing map kinase inhibitors | SCIOS, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| US-7220763-B2 | Indole-type derivatives as inhibitors of p38 kinase | SCIOS, INC. (US) | 2007-05-22 | — | — | US | disclosed |
| US-7220763-B2 | Indole-type derivatives as inhibitors of p38 kinase | SCIOS, INC. (US) | 2007-05-22 | — | — | US | disclosed |
| US-7220763-B2 | Indole-type derivatives as inhibitors of p38 kinase | SCIOS, INC. (US) | 2007-05-22 | — | — | US | disclosed |
| EP-1545528-A4 | INDOLE-TYPE DERIVATIVES AS INHIBITORS OF P38 KINASE | SCIOS INC (US) | 2006-07-26 | — | — | EP | disclosed |
| EP-1545528-A2 | INDOLE-TYPE DERIVATIVES AS INHIBITORS OF P38 KINASE | SCIOS INC. (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20040142940-A1 | Indole-type derivatives as inhibitors of p38 kinase | SCIOS, INC. | 2004-07-22 | — | — | US | disclosed |
| WO-2004022712-A2 | INDOLE-TYPE DERIVATIVES AS INHIBITORS OF p38 KINASE | SCIOS INC. (US) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140357638-A1 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | APP, PSEN1, PSEN2 | MAPK14 4676/4885MAPK11 4249/4885MAPK13 4673/4885 |
| US-20040142940-A1 | Indole-type derivatives as inhibitors of p38 kinase | MAPK1, MAPKAPK2, MAPK4 | MAPK14 28/4885MAPK11 48/4885MAPK13 38/4885 |
| US-20120289511-A1 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | APP, PSEN1, PSEN2 | MAPK14 4676/4885MAPK11 4249/4885MAPK13 4673/4885 |
| US-20160030431-A1 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | APP, PSEN1, PSEN2 | MAPK14 4676/4885MAPK11 4249/4885MAPK13 4673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.